Sign In
Buy TGTX
$40.11
+3.47 (+9.47%)
At Close: Jun 03, 2026
TG Therapeutics, Inc. (TGTX) Q4 2022 Earnings Call Transcript
02:06pm, Tuesday, 28'th Feb 2023
TG Therapeutics, Inc. (NASDAQ:TGTX ) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ET Company Participants Jenna Bosco – Investor Relations Michael Weiss – Chairman and Chief Executiv
TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates
02:05pm, Tuesday, 28'th Feb 2023 Zacks Investment Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -50% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
12:30pm, Tuesday, 28'th Feb 2023 GlobeNewswire Inc.
Conference call to be held today, Tuesday, February 28, 2023, at 8:30 AM ET Conference call to be held today, Tuesday, February 28, 2023, at 8:30 AM ET
Universal Health Services (UHS) Tops Q4 Earnings and Revenue Estimates
10:45pm, Monday, 27'th Feb 2023 Zacks Investment Research
Universal Health Services (UHS) delivered earnings and revenue surprises of 2.03% and 1.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the sto
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2022 Financial Results and Business Update
12:30pm, Friday, 24'th Feb 2023 GlobeNewswire Inc.
Conference call to be held Tuesday, February 28, 2023 at 8:30 AM ET Conference call to be held Tuesday, February 28, 2023 at 8:30 AM ET
NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ubl
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2022 Financial Results and Business Update
07:30am, Friday, 24'th Feb 2023
Conference call to be held Tuesday, February 28, 2023 at 8:30 AM ET Conference call to be held Tuesday, February 28, 2023 at 8:30 AM ET
TG Therapeutics (TGTX) Outpaces Stock Market Gains: What You Should Know
11:00pm, Wednesday, 15'th Feb 2023 Zacks Investment Research
TG Therapeutics (TGTX) closed at $19.34 in the latest trading session, marking a +1.79% move from the prior day.
Biotech Growth Stock Boosted By FDA Approval For Multiple Sclerosis Treatment
02:46pm, Wednesday, 15'th Feb 2023
Growth stock TG Therapeutics has surged 80% after FDA approval for its multiple sclerosis treatment. The post Biotech Growth Stock Boosted By FDA Approval For Multiple Sclerosis Treatment appeared fir
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evalu
Top 5 Health Care Stocks That May Collapse In February
12:14pm, Monday, 13'th Feb 2023 Benzinga
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
The RSI is a momentum indicator, which compares a stock's strength on days when
Cramer Likens This Stock To 'A Fine Merlot': It's Down 1% In 2023, So 'I Would Buy All You Can Right Here'
02:19pm, Wednesday, 08'th Feb 2023 Benzinga
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Parker-Hannifin Corp (NYSE: PH) is "just the kind of industrial I’ve been recommending."
When asked about ConocoPhillips (NYSE: COP), he s
TG Therapeutics Stock 300% Rally Has Legs Yet
08:46am, Wednesday, 08'th Feb 2023
It's been a while since the Marketbeat team flagged a hot stock that had already logged a 300% rally but looked like it was going to go higher. But the New York-headquartered TG Therapeutics Inc (NASD
TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You Should Know
11:00pm, Tuesday, 07'th Feb 2023 Zacks Investment Research
TG Therapeutics (TGTX) closed the most recent trading day at $18.43, moving -0.27% from the previous trading session.
TG Therapeutics: Strategy After Briumvi Launch
12:22pm, Wednesday, 01'st Feb 2023
After a year of churn and doldrums, TG Therapeutics, Inc. finally got approval for, and launched, briumvi or ublituximab in RRMS. I am trying to decide what to do with my TG Therapeutics shares, now t
